FindMyRecallSubscribe
Class I: serious health riskTerminated

Adamis Pharmaceuticals Symjepi Recall

SYMJEPI (epinephrine injection, USP) 0

Adamis Pharmaceuticals Corporation · San Diego, CA

Risk level
Class I
Reported by FDA
Apr 13, 2022
Recall ID
D-0764-2022
Check your lot numberHow we source this data

Summary

Adamis Pharmaceuticals recalled Symjepi starting Mar 21, 2022. The FDA classified it as Class I (serious health risk) and published enforcement report D-0764-2022 on Apr 13, 2022. Reason: Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine. Status: Terminated.

Why it was recalled

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

Product description

SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02.

Lot numbers, UPCs & expiration codes

Lot # 21101Y, Exp. 11/30/2022

Where it was sold

Nationwide in the U.S.A.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0764-2022
Classification
Class I
Status
Terminated
Recall initiated
Mar 21, 2022
FDA report date
Apr 13, 2022
Quantity
2,500 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Adamis Pharmaceuticals Corporation

Original FDA data

Every field from FDA enforcement report D-0764-2022, exactly as published.

Show all FDA fields
City
San Diego
State
CA
Status
Terminated
Country
United States
Event ID
89778
Address
11682 El Camino Real Ste 300
Code information
Lot # 21101Y, Exp. 11/30/2022
Postal code
92130-2092
Report date
Apr 13, 2022
Product type
Drugs
Recall number
D-0764-2022
Classification
Class I
Recalling firm
Adamis Pharmaceuticals Corporation
Product quantity
2,500 cartons
Termination date
Feb 8, 2023
Reason for recall
Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.
Voluntary / mandated
Voluntary: Firm initiated
Product description
SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02.
Distribution pattern
Nationwide in the U.S.A.
Recall initiation date
Mar 21, 2022
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Apr 8, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0764-2022, published Apr 13, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls